Oral cancers (OC) are among the most frequent malignancies encountered in Southeast Asia, primarily due to the prevalent habit of betel quid (BQ) and smokeless tobacco use in this region. Areca nut (AN), the primary ingredient in BQ, contains several alkaloids, including arecoline, arecaidine, guvacoline, and guvacine. These have been associated with both the AN abuse liability and carcinogenicity. Additionally, variations in AN alkaloid levels could lead to differences in the addictiveness and carcinogenic potential across various AN-containing products. Recent studies based on animal models and in vitro experiments show cellular and molecular effects induced by AN. These comprise promoting epithelial-mesenchymal transition, autophagy initiation, tissue hypoxia, genotoxicity, cytotoxicity, and cell death. Further, clinical research endorses these undesired harmful effects in humans. Oral submucosal fibrosis, a potentially malignant disease of the oral cavity, is predominantly reported from the geographical areas of the globe where AN is habitually chewed. OC in chronic AN users presents a more aggressive phenotype, such as resistance to anti-cancer drugs. The available evidence on the carcinogenicity of AN based on the findings reported in the recently published experimental studies is discussed in the present review.

No abstract

Oral squamous cell carcinoma (OSCC) is one of the most common epithelial malignancies of multifactorial etiology linked with considerable mortality and morbidity. Generally, OSCC arises from pre-existing oral lesions quoted as oral potentially malignant disorders. Early diagnosis of OSCC is an attractive strategy to increase the survival rate of patients. Despite the accessibility of prominent diagnostic tools, many factors restrain the successful application of these approaches. The discovery of novel alternative methods to diagnose cancer definitively with higher selectivity and sensitivity has aroused scientific interest. Metabolomics is an unbiased analytical approach for qualitative and quantitative analyses of different metabolites in cells, tissues, or biological fluids and their alterations in response to pathophysiological stimuli. Several coupled techniques, together with chromatographic platforms, have facilitated metabolic profiling and, at the same time, detected cancer biomarkers, which are crucial for an effective treatment process. This overview discusses some of the most recent technological advances in metabolomics and focuses on their application to reveal the underlying causes of OSCC and their potential implications for personalised medicine.

Around 600 million people globally chew betel quid (BQ). Three-quarters of its consumption is concentrated in the countries of the Pacific islands, South and Southeast Asia (Auluck et al., 2009). This habit begins at a very young age of almost 13 years and makes adolescents a high-risk group (Sorensen et al., 2005). BQ has a known relaxing and stimulating effect by acting on the autonomic nervous system (Winstock, 2002). The formulation of BQ depends on a variety of factors, which can include the cultural background of the country, regional background, personal preferences, and the availability of certain ingredients. It usually consists of betel leaf, betel/areca nut, slaked lime with or without tobacco (IARC, 2004). Commonly available products are; paan (preparation combining betel leaf with areca nut with/without tobacco), paan masala, supari, chaaliya, guthka and other

Background and AimsCytotoxicity is a key disadvantage of using chemotherapeutic drugs to treat cancer. This can be overcome by encapsulating chemotherapeutic drugs in suitable carriers for targeted delivery, allowing them to be released only at the cancerous sites. Herein, we aim to review the recent scientific developments in the utilization of nanotechnology‐based drug delivery systems for treating oral malignancies that can lead to further improvements in clinical practice.MethodsA comprehensive literature search was conducted on PubMed, Google Scholar, ScienceDirect, and other notable databases to identify recent peer‐reviewed clinical trials, reviews, and research articles related to nanoplatforms and their applications in oral cancer treatment.ResultsNanoplatforms offer a revolutionary strategy to overcome the challenges associated with conventional oral cancer treatments, such as poor drug solubility, non‐specific targeting, and systemic toxicity. These nanoscale drug delivery systems encompass various formulations, including liposomes, polymeric nanoparticles, dendrimers, and hydrogels, which facilitate controlled release and targeted delivery of therapeutic agents to oral cancer sites. By exploiting the enhanced permeability and retention effect, Nanoplatforms accumulate preferentially in the tumor microenvironment, increasing drug concentration and minimizing damage to healthy tissues. Additionally, nanoplatforms can be engineered to carry multiple drugs or a combination of drugs and diagnostic agents, enabling personalized and precise treatment approaches.ConclusionThe utilization of nanoplatforms in oral cancer treatment holds significant promise in revolutionizing therapeutic strategies. Despite the promising results in preclinical studies, further research is required to evaluate the safety, efficacy, and long‐term effects of nanoformulations in clinical settings. If successfully translated into clinical practice, nanoplatform‐based therapies have the potential to improve patient outcomes, reduce side effects, and pave the way for more personalized and effective oral cancer treatments.